JP2022525651A5 - - Google Patents
Info
- Publication number
- JP2022525651A5 JP2022525651A5 JP2021556400A JP2021556400A JP2022525651A5 JP 2022525651 A5 JP2022525651 A5 JP 2022525651A5 JP 2021556400 A JP2021556400 A JP 2021556400A JP 2021556400 A JP2021556400 A JP 2021556400A JP 2022525651 A5 JP2022525651 A5 JP 2022525651A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- gene
- genetically modified
- hiv
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024163218A JP2024175115A (ja) | 2019-03-19 | 2024-09-20 | Cd4欠損car t細胞および抗cd4 car t細胞を作製するための方法および組成物ならびにその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962820387P | 2019-03-19 | 2019-03-19 | |
| US62/820,387 | 2019-03-19 | ||
| PCT/US2020/023117 WO2020190925A1 (en) | 2019-03-19 | 2020-03-17 | Methods and compositions for engineering cd4-deficient car t cells and anti-cd4 car t cells and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024163218A Division JP2024175115A (ja) | 2019-03-19 | 2024-09-20 | Cd4欠損car t細胞および抗cd4 car t細胞を作製するための方法および組成物ならびにその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022525651A JP2022525651A (ja) | 2022-05-18 |
| JP2022525651A5 true JP2022525651A5 (cg-RX-API-DMAC7.html) | 2024-01-30 |
Family
ID=72519342
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556400A Pending JP2022525651A (ja) | 2019-03-19 | 2020-03-17 | Cd4欠損car t細胞および抗cd4 car t細胞を作製するための方法および組成物ならびにその使用 |
| JP2024163218A Pending JP2024175115A (ja) | 2019-03-19 | 2024-09-20 | Cd4欠損car t細胞および抗cd4 car t細胞を作製するための方法および組成物ならびにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024163218A Pending JP2024175115A (ja) | 2019-03-19 | 2024-09-20 | Cd4欠損car t細胞および抗cd4 car t細胞を作製するための方法および組成物ならびにその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12703735B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3941486A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022525651A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020190925A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025504343A (ja) * | 2021-12-30 | 2025-02-12 | 重▲慶▼精准生物技▲術▼有限公司 | ユニバーサルcar-t細胞の調製技術及びその使用 |
| CN116410932A (zh) * | 2021-12-30 | 2023-07-11 | 重庆精准生物技术有限公司 | 一种通用型car-t细胞的制备方法及其应用 |
| CN116410931A (zh) * | 2021-12-30 | 2023-07-11 | 重庆精准生物技术有限公司 | 一种通用型car-t细胞的制备技术及其应用 |
| CN118662607B (zh) * | 2023-03-15 | 2026-07-07 | 中国科学院上海药物研究所 | 抑制过激炎性反应的蛋白及其应用 |
| WO2026032970A1 (en) * | 2024-08-07 | 2026-02-12 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Cd4-specific chimeric antigen receptor and methods and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710169B2 (en) * | 1987-10-02 | 2004-03-23 | Genentech, Inc. | Adheson variants |
| EP3027755B1 (en) | 2013-08-02 | 2019-10-09 | The Regents of The University of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| SG10201808811QA (en) | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
| WO2015167766A1 (en) | 2014-04-29 | 2015-11-05 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor (car) derived from broadly neutralizing antibodies |
| ES2836743T3 (es) | 2014-06-02 | 2021-06-28 | Us Health | Receptores de antígeno quiméricos que seleccionan como diana CD-19 |
| CA2977106A1 (en) * | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
| US10648020B2 (en) | 2015-06-18 | 2020-05-12 | The Broad Institute, Inc. | CRISPR enzymes and systems |
| MX2018001568A (es) | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| US9512446B1 (en) | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| WO2017044776A1 (en) * | 2015-09-10 | 2017-03-16 | Texas Tech University System | Single-guide rna (sgrna) with improved knockout efficiency |
| US20180371052A1 (en) | 2015-12-22 | 2018-12-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| MX2018010484A (es) | 2016-03-04 | 2019-01-10 | Editas Medicine Inc | Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer. |
| WO2017172952A1 (en) | 2016-04-01 | 2017-10-05 | Promab Biotechnologies, Inc. | Flag tagged cd19-car-t cells |
| US12350349B2 (en) | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| WO2019106522A1 (en) * | 2017-11-28 | 2019-06-06 | Novartis Ag | Pooled crispr/cas9 screening in primary cells using guide swap technology |
-
2020
- 2020-03-17 WO PCT/US2020/023117 patent/WO2020190925A1/en not_active Ceased
- 2020-03-17 EP EP20774852.6A patent/EP3941486A4/en active Pending
- 2020-03-17 US US17/435,535 patent/US12703735B2/en active Active
- 2020-03-17 JP JP2021556400A patent/JP2022525651A/ja active Pending
-
2024
- 2024-09-20 JP JP2024163218A patent/JP2024175115A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022271376B9 (en) | CRISPR/CAS-related methods and compositions for treating herpes simplex virus | |
| EP4176048B1 (en) | Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence | |
| JP7252328B2 (ja) | Rnaを編集する方法および組成物 | |
| Dabiri et al. | Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies | |
| JP6929791B2 (ja) | エピゲノム編集のための組成物および方法 | |
| JP7553440B2 (ja) | 抗cd33免疫細胞癌療法 | |
| JP2023055884A5 (cg-RX-API-DMAC7.html) | ||
| JP2024097924A (ja) | 抗ptk7免疫細胞癌療法 | |
| JP7471289B2 (ja) | 抗liv1免疫細胞癌療法 | |
| JP2021518102A5 (cg-RX-API-DMAC7.html) | ||
| JP2016520319A5 (cg-RX-API-DMAC7.html) | ||
| JP2021518162A5 (cg-RX-API-DMAC7.html) | ||
| JP2022519595A5 (cg-RX-API-DMAC7.html) | ||
| RU2019133280A (ru) | Композиции и способы для иммуноонкологии | |
| JP2021518160A5 (cg-RX-API-DMAC7.html) | ||
| JP2022521787A (ja) | Rna誘導型エンドヌクレアーゼを使用するdna組み込みのための改善された方法 | |
| JP2021502077A5 (cg-RX-API-DMAC7.html) | ||
| JP2024511131A5 (cg-RX-API-DMAC7.html) | ||
| JP2022525651A (ja) | Cd4欠損car t細胞および抗cd4 car t細胞を作製するための方法および組成物ならびにその使用 | |
| TW202417626A (zh) | 具有共表現的tgfbr shrna之免疫細胞 | |
| KR102264115B1 (ko) | 무-운반체 다중 CRISPR/Cas 9 유전자 편집 복합체 및 그의 용도 | |
| CN118871583A (zh) | 修饰的基于crispr的基因编辑系统及其使用方法 | |
| JP2020513849A5 (cg-RX-API-DMAC7.html) | ||
| AU2018231559A1 (en) | Extracellular matrix-producing composition using MAST4 gene and preparation method therefor | |
| US11053503B2 (en) | Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition |